Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With KRAS G12C Mutations”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Testing effectiveness (Phase 2)Looking for participantsNCT06244771
What this trial is testing

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more
Frontier Medicines Corporation 403
Early research (Phase 1)Looking for participantsNCT06720987
What this trial is testing

Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Who this might be right for
KRAS G12C MutationKRAS G12S MutationSolid Tumor Malignancies+1 more
Kumquat Biosciences Inc. 128
Testing effectiveness (Phase 2)Active Not RecruitingNCT03785249
What this trial is testing

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 731
Early research (Phase 1)Study completedNCT05178888
What this trial is testing

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Who this might be right for
Advanced Solid Tumor
Mirati Therapeutics Inc. 11
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Early research (Phase 1)Active Not RecruitingNCT04380753
What this trial is testing

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Who this might be right for
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Amgen 12
Early research (Phase 1)Active Not RecruitingNCT04185883
What this trial is testing

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Who this might be right for
Advanced Solid TumorsKirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen 610
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 311
Testing effectiveness (Phase 2)Study completedNCT05002270
What this trial is testing

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNSCLCCRC
Jacobio Pharmaceuticals Co., Ltd. 29
Early research (Phase 1)Active Not RecruitingNCT05010694
What this trial is testing

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Who this might be right for
Advanced Solid Tumors Harboring With G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05194995
What this trial is testing

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Colorectal CancerSmall Intestinal CancerAppendiceal Cancer
Allist Pharmaceuticals, Inc. 48
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Testing effectiveness (Phase 2)Looking for participantsNCT05410145
What this trial is testing

D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd 442
Testing effectiveness (Phase 2)Looking for participantsNCT06008288
What this trial is testing

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Who this might be right for
KRAS P.G12CPancreatic CancerSolid Tumor
Allist Pharmaceuticals, Inc. 88
Testing effectiveness (Phase 2)UnknownNCT05119933
What this trial is testing

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 55
Early research (Phase 1)Ended earlyNCT05480865
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Who this might be right for
Solid Tumor, AdultMetastatic Solid TumorMetastatic NSCLC+1 more
Navire Pharma Inc., a BridgeBio company 28
Early research (Phase 1)Active Not RecruitingNCT04449874
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung CancerColorectal CancerAdvanced Solid Tumors
Genentech, Inc. 498
Testing effectiveness (Phase 2)Looking for participantsNCT06162221
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc. 616
Early research (Phase 1)UnknownNCT05768321
What this trial is testing

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumors
GenEros Biopharma Hangzhou Ltd 70
Load More Results